R. Michael Carruthers's most recent trade in Elevation Oncology Inc was a trade of 35,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Elevation Oncology Inc | R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| OnKure Therapeutics Inc. -... | R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 7,650 | 7,650 | - | - | Stock Option (right to buy) | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 5,209 | 0 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 5,209 | 82,328 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.45 per share. | 01 May 2025 | 1,314 | 81,014 | - | 16.5 | 21,621 | Common Stock |
| Edgewise Therapeutics Inc | Carruthers R. Michael | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.71 per share. | 11 Oct 2024 | 70,000 | 76,904 | - | 0.7 | 49,700 | Common Stock |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 70,000 | 127,122 | - | - | Stock Option (Right to Buy) | |
| OnKure Therapeutics Inc. -... | R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 15,300 | 15,300 | - | - | Stock Option (right to buy) | |
| OnKure Therapeutics Inc. -... | R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 4,065 | 4,939 | - | - | Class A Common Stock | |
| OnKure Therapeutics Inc. -... | R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 1,760 | 1,760 | - | - | Stock Option (right to buy) | |
| OnKure Therapeutics Inc. -... | R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 1,324 | 1,324 | - | - | Stock Option (right to buy) | |
| OnKure Therapeutics Inc. -... | R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 874 | 874 | - | - | Class A Common Stock | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2024 | 96,068 | 40,990 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.55 per share. | 20 Sep 2024 | 50,000 | 6,904 | - | 28.5 | 1,427,385 | Common Stock |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 20 Sep 2024 | 50,000 | 56,904 | - | 1.9 | 96,500 | Common Stock |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.59 per share. | 20 Sep 2024 | 46,068 | 35,928 | - | 28.6 | 1,316,909 | Common Stock |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 20 Sep 2024 | 46,068 | 81,996 | - | 1.9 | 88,911 | Common Stock |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.59 per share. | 20 Sep 2024 | 24,960 | 6,904 | - | 28.6 | 713,512 | Common Stock |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.59 per share. | 20 Sep 2024 | 4,064 | 31,864 | - | 28.6 | 116,174 | Common Stock |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 138,750 | 138,750 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 23,125 | 23,125 | - | - | Restricted Stock Units | |
| Elevation Oncology Inc | R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 5,208 | 37,387 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 5,208 | 5,209 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.91 per share. | 01 May 2024 | 2,157 | 35,230 | - | 18.9 | 40,789 | Common Stock |
| Edgewise Therapeutics Inc | Carruthers Michael R. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2024 | 90,000 | 137,058 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 23 Jan 2024 | 90,000 | 119,024 | - | 1.9 | 173,700 | Common Stock |
| Edgewise Therapeutics Inc | Michael R. Carruthers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 23 Jan 2024 | 90,000 | 29,024 | - | 15.8 | 1,419,759 | Common Stock |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.71 per share. | 22 Jun 2023 | 10,000 | 29,024 | - | 0.7 | 7,100 | Common Stock |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2023 | 10,000 | 197,122 | - | - | Stock Options (Right to buy) | |
| Elevation Oncology Inc | R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 31,238 | 31,238 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 5,208 | 17,462 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 5,208 | 10,417 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.90 per share. | 01 May 2023 | 1,336 | 16,126 | - | 8.9 | 11,897 | Common Stock |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2022 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Elevation Oncology Inc | R. Michael Carruthers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 15,619 | 15,619 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2022 | 9,000 | 207,122 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.71 per share. | 23 May 2022 | 9,000 | 12,000 | - | 0.7 | 6,390 | Common Stock |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2022 | 15,625 | 15,625 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | R. Michael Carruthers | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) |